Law
Offices of Howard G. Smith announces an investigation on behalf of
investors of Revance Therapeutics, Inc. ("Revance" or the "Company")
(NASDAQ: RVNC) concerning the Company’s and its officers’ possible
violations of federal securities laws.
The investigation focuses on the allegedly misleading statements found
in the Company’s public statements and SEC filings which failed to
disclose, among other things, that: (i) Revance had not commenced a
Phase 3 clinical trial of RT001—its lead product under development for
the treatment of wrinkles around the eyes—in the first quarter of 2014;
and (ii) Revance did not have the quality or quantity of RT001 on hand
sufficient to complete and successful Phase 3 clinical trial. When the
true details entered the market, the Company’s share price declined
sharply and investors suffered damages.
If you purchased Revance securities, have information or would like to
learn more about these claims, or have any questions concerning this
announcement or your rights or interests with respect to these matters,
please contact Howard G. Smith, Esquire, of Law Offices of Howard G.
Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by
telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com,
or visit our website at http://www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150903006129/en/
Copyright Business Wire 2015